Onconetix, Inc.
No SEC Form 4 filings for $ONCO in the last 30 days.
See all $ONCO insider activity →Onconetix, Inc. (ONCO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Filed by Onconetix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: Onconetix, Inc. Commission File No.: 001-41294 Date: September 14,2026 Onconetix Provi
Onconetix, Inc. (ONCO) announced that Realbotix LLC, its pending acquisition target, has launched a pilot program with a European telecom firm to deploy AI-powered humanoid robots in live events. The pilot will evaluate robots' ability to present, host, and engage with audiences. Onconetix aims to complete the acquisition in the second half of 2026, subject to approvals. ONCO stock is currently at $0.70, up 3.86%.
Onconetix, Inc. (ONCO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement PIPE Financing On July 28, 2026, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor (the “ PIPE Investor ”
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ONCO (Onconetix, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ONCO coverage spans financial news, corporate actions and mergers & acquisitions.
Bridge financing reduces cash needed at closing and signals progress on the acquisition.
Pilot launch may boost confidence in the acquisition and support ONCO's share price.
The filing discloses a large equity issuance facility with VWAP-based purchase mechanics and a 19.99% cap, which can pressure dilution expectations.
The contract is a positive execution/capability signal for ONC010 CMC and scale-up, but it does not disclose milestones, timelines, or funding amounts.
Onconetix's 1-for-10 reverse split aims to meet Nasdaq's minimum bid price requirement, which historically has been followed by negative market reactions.
AlphAI scores every news story that mentions ONCO with an AI model for sentiment and relevance, and aggregates insider trades from Onconetix, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Onconetix, Inc. (ONCO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Filed by Onconetix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: Onconetix, Inc. Commission File No.: 001-41294 Date: September 14,2026 Onconetix Provi
2 min readOnconetix, Inc. (ONCO) announced that Realbotix LLC, its pending acquisition target, has launched a pilot program with a European telecom firm to deploy AI-powered humanoid robots in live events. The pilot will evaluate robots' ability to present, host, and engage with audiences. Onconetix aims to complete the acquisition in the second half of 2026, subject to approvals. ONCO stock is currently at $0.70, up 3.86%.
1 min readOnconetix, Inc. (ONCO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement PIPE Financing On July 28, 2026, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor (the “ PIPE Investor ”
6 min readOnco-Innovations Limited said it signed a services agreement with Nanosoft Polymers to support development of ONC010, its lead nanoparticle-formulated PNKP inhibitor. Nanosoft will handle polymer process development, analytical characterization, scale-up, formulation optimization and technology transfer for Onco’s PEO-PBCL platform, aiming to strengthen IND-enabling CMC and future GMP readiness.
3 min readOnconetix (NASDAQ: ONCO) announced a 1-for-10 reverse stock split, effective May 21, 2026, to meet Nasdaq's $1.00 minimum bid price requirement. This split will reduce outstanding shares from approximately 11.4 million to 1.14 million, with fractional shares being cashed out. Historically, such reverse splits by Onconetix have been followed by negative market reactions, signaling investor caution.
2 min readOnconetix (ONCO) announced that Karina Fedasz will step down as interim CEO, with David White appointed as her successor, effective March 18. Fedasz will remain as interim CFO. Sammy Dorf has also been appointed to the company's board of directors and audit committee.
2 min readOnconetix's subsidiary, Proteomedix AG, has amended its license agreement with Labcorp for a new validation study of Proclarix, a prostate cancer risk identification tool. Under the amendment, Labcorp will not pay royalties, and Onconetix will compensate Labcorp up to $300,000 based on milestone achievements. Spark, TipRanks’ AI Analyst, currently rates ONCO as an "Underperform" due to financial difficulties and a bearish technical trend.
4 min readCINCINNATI, OH, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Onconetix, Inc. ( Nasdaq: ONCO ) ( "Onconetix" or the "Company" ) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, announced the ...
3 min readCINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Onconetix, Inc. ( Nasdaq: ONCO ) , a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the ...
3 min readNEW YORK, July 17, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
3 min read
